Detalhe da pesquisa
1.
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.
Blood
; 2024 May 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38728378
2.
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.
Blood
; 142(14): 1208-1218, 2023 10 05.
Artigo
Inglês
| MEDLINE | ID: mdl-37366170
3.
Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study.
Blood
; 137(11): 1527-1537, 2021 03 18.
Artigo
Inglês
| MEDLINE | ID: mdl-33512409
4.
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice.
Am J Hematol
; 98(5): 720-729, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36708469
5.
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach.
Am J Hematol
; 98(3): 421-431, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36588413
6.
A prospective study of dysgeusia and related symptoms in patients with multiple myeloma after autologous hematopoietic cell transplantation.
Cancer
; 128(21): 3850-3859, 2022 11 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36041227
7.
Pilot Study of Telehealth Evaluations in Patients Undergoing Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 26(6): e135-e137, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32070723
8.
Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma.
Biol Blood Marrow Transplant
; 26(11): 2040-2046, 2020 11.
Artigo
Inglês
| MEDLINE | ID: mdl-32712326
9.
Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.
Biol Blood Marrow Transplant
; 26(8): 1394-1401, 2020 08.
Artigo
Inglês
| MEDLINE | ID: mdl-32442725
10.
Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma.
Biol Blood Marrow Transplant
; 24(7): 1379-1385, 2018 07.
Artigo
Inglês
| MEDLINE | ID: mdl-29410301
11.
Involved free light chains <10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis.
Am J Hematol
; 96(1): E20-E23, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33068021
12.
Older patients with myeloma derive similar benefit from autologous transplantation.
Biol Blood Marrow Transplant
; 20(11): 1796-803, 2014 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-25046833
13.
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
Blood Adv
; 8(7): 1600-1611, 2024 Apr 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37878808
14.
Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy.
Blood Adv
; 2024 Apr 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38598713
15.
Unscheduled healthcare interactions in multiple myeloma patients receiving T cell redirection therapies.
Blood Adv
; 2024 Apr 12.
Artigo
Inglês
| MEDLINE | ID: mdl-38621239
16.
Moving towards establishing centres of excellence in cardiac amyloidosis: an International Cardio-Oncology Society statement.
Heart
; 110(12): 823-830, 2024 May 23.
Artigo
Inglês
| MEDLINE | ID: mdl-38267197
17.
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma.
Blood Cancer J
; 14(1): 84, 2024 May 27.
Artigo
Inglês
| MEDLINE | ID: mdl-38802346
18.
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.
Blood Cancer J
; 14(1): 88, 2024 May 31.
Artigo
Inglês
| MEDLINE | ID: mdl-38821925
19.
Novel iatrogenic amyloidosis caused by peptide drug liraglutide: a clinical mimic of AL amyloidosis.
Haematologica
; 103(12): e610-e612, 2018 12.
Artigo
Inglês
| MEDLINE | ID: mdl-30262557
20.
Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.
Blood Cancer J
; 13(1): 112, 2023 07 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37491332